Otonomy, Inc. (NASDAQ:OTIC) management will conduct a conference call for 4th November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.otonomy.com
Earnings Expectation
Otonomy, Inc. is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.24 per share from revenue of $ 0.05 million. Looking ahead, the full year loss are expected at $ 1.21 per share on the revenues of $ 0.58 million.
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménières disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
